Comparative Pharmacology
Head-to-head clinical analysis: COLOCORT versus ORASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLOCORT versus ORASONE.
COLOCORT vs ORASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colocort (hydrocortisone acetate) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as prostaglandins and leukotrienes, and suppression of immune responses.
Orasone (prednisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
10 mg rectally administered once daily, preferably at bedtime, as a retention enema.
Adults: 5-60 mg orally once daily or divided twice daily; typical starting dose 5-40 mg/day. Route: oral. Frequency: once daily or every 12 hours.
None Documented
None Documented
Clinical Note
moderateDiflorasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Gatifloxacin."
Clinical Note
moderateDiflorasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Rosoxacin."
Clinical Note
moderateDiflorasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Levofloxacin."
Clinical Note
moderateDiflorasone + Trovafloxacin
Terminal elimination half-life: 2.5–3.5 hours (mean ~3 hours). No active metabolites, so duration of action correlates with half-life.
Terminal half-life of 3-4 hours for prednisolone (active metabolite of ORASONE); clinically, duration of HPA-axis suppression is more relevant (12-36 hours) with longer effects at higher doses.
Renal: ~30% as metabolites; fecal/biliary: ~20% as metabolites; remainder metabolized with minimal unchanged drug excreted.
Primarily renal: ~80% as 17-keto metabolites and unchanged drug; biliary/fecal excretion accounts for <10%.
Category C
Category C
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Trovafloxacin."